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EXECUTIVE SUMMARY
INTRODUCTION 
Many sub-Sahara African health markets are trapped in a vicious cycle and perennial disconnect 
amongst potential supply, demand 
and investments dynamics that could 
concomitantly support local pharmaceutical 
technological upgrading whilst at the same 
time improving social inclusion, healthcare 
access and ultimately local health security. 
As of 2019, Africa has: more than 50% of 
all health expenses paid out of pocket; 
more than 80% of the global burden of 
non-communicable diseases; more than 
15% of the world’s population; 47% of the 
global burden of communicable diseases; 
yet has less than 2% of global health 
expenditure (PAF, 2019). To compound 
this and the current burden for the health 
sector, the African continent will in the 
next few decades enter multiple transition 
phases that impact health security. These 
include demographic and disease transitions 
as populations’ age and as infectious 
diseases begin to be overshadowed by 
non-communicable diseases, in addition to 
the impact of chronic infections on non-
communicable diseases such as cancer. 
The aforementioned are juxtaposed on 
technology/innovation transitions such as 
the fourth industrial revolution, big data, 
artificial intelligence, which will change 
curricula requirements and skills and further 
complicate rural-urban and transcontinental 
migration challenges.
In many instances, as a (semi-) public 
good, the healthcare and its allied 
industry complex requires government 
intervention through policy and practice. 
However, many African countries face 
challenges with especially limited state 
financial and technical capabilities as well 
as commensurate institutions. 
The current health-industry complex 
(by which we mean the infrastructures, 
linkages, synergies and capabilities in 
place to manufacture, supply and deliver 
health products to the health system 
that addresses local health challenges) 
is not geared to adequately address 
current and more importantly complex 
emerging African health challenges. 
The supply of medicines based on 
local manufacturing, procurement and 
distribution capabilities, and dispensing 
to patients in health facilities of different 
forms, is presently not matching 
demand, and will get more constrained 
with the challenges ushered in by the 
aforementioned multiple social and 
technological/innovation transitions. In 
response, African countries will need 
to accelerate local production of drugs, 
vaccines and other health technologies 
to cater for emerging and long-term 
health challenge. 
The current health-industry complex 
architecture will not be able to rapidly 
achieve; invariably it means new and 
This policy brief draws from a 
Scinnovent Centre commissioned 
study, a component of the broader 
African Science Granting Councils 
Initiative (SGCI) Theme 3.
This study demonstrates the role 
of private public partnerships 
(PPPs) in addressing global and 
local health inequity through 
market adjustment, and 
exemplifies the importance 
of local embedment of local 
pharmaceutical suppliers/
manufacturers among poor 
populations in low-middle income 
countries to drive sustainable 
social inclusion and local health 
security. 
The study also unpacks the 
context-specific social, economic, 
political, geographic, and 
epidemiological factors that 
cannot be successfully examined 
without anchoring the lens on the 
sub-regional, regional and global 
political economies.
The study thus expands literature 
for the southern African region 
hitherto disproportionately 
focused on public-private 
engagement in South Africa with 
little known about the other 
countries, outside of Zimbabwe 
and Mozambique.
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innovative business and funding 
models, as well as organisational 
arrangements that engender 
competitiveness whilst at the same 
time promoting social inclusion and 
local health security are required.
 Evidence is accumulating on the 
role and influence of public-private 
partnerships (PPPs) as innovative 
mechanisms for availing financing, 
capabilities and innovative 
business models and organisational 
architectures necessary for an agile 
health-industry complex critical for 
African socio-economic development.
PURPOSE OF THE BRIEF
The nexus between health and 
industrialization is under-studied in 
Africa and other most developing 
countries (Mackintosh et al, 2018). 
There is scant empirical research on 
how industrial change (or industrial 
development) can aid (transform) 
public health, particularly in terms 
of reducing the costs of local 
manufacturing of medicines and 
medical equipment. 
This Policy Brief provides new 
empirical data and evidence on how 
PPPs contribute in the delivery of 
health and industrial policies and 
programmes for health and well-
being. The commissioned study 
explored the role PPPs can play as 
innovative technological catch-up and 
investment financing mechanisms 
to build a competitive African health 
sector that is interlinked with a 
vibrant local pharmaceutical industry 
complex, capable of supplying 
drugs, vaccines and other health 
technologies that promote accelerated 
social inclusion and health security. 
We use co-produced primary and 
secondary qualitative and quantitative 
evidence from five southern African 
countries, namely Botswana, Namibia, 
South Africa, Zambia and Zimbabwe 
to highlight and examine examples, 
opportunities, successes, failures 
of and lessons from PPPs in health-
industry innovation and health system 
financing.
Health in Southern Africa
The five study countries are all 
members of the Southern African 
Development Community (SADC); a 
region with an estimated 337.1 million 
inhabitants (2017 estimate) facing 
high morbidity and mortality rates, 
low nutrition status, poor healthcare 
infrastructure and services, and poor 
living conditions as major challenges.
 
The region has for the past three 
decades faced a challenging and 
persistent HIV/AIDS pandemic, and it 
is not surprising that the pandemic 
permeates and influences most factors 
of development in the region. The 
SADC region accounts for one-third 
of all people living with HIV and AIDS 
worldwide; while eight SADC Member 
States are among those countries 
with the highest rates of tuberculosis; 
and 75% of the SADC population is 
at risk of contracting malaria. It is 
estimated that the loss of productivity 
attributable to tuberculosis is up to 7% 
of gross domestic product (GDP) for 
some countries, while the HIV/AIDS 
challenge depressed the GDP of most 
Sub-Saharan African countries by up 
to 20% in the decade 2001 to 2010 
(WHO, 2013).
The health care systems of the five 
study countries, are continuously 
in need of strengthening due 
to challenges embedded in or 
transcending the systems (Mugwagwa, 
Banda and Chinyadza, 2017). The 
countries are all facing a number 
of similar challenges with respect 
to health delivery, presenting both 
objective and subjective reasons for 
inclusion in the study informing this 
Brief. 
Pharmaceuticals
The African pharmaceutical market 
is thought to be around USD 40 – 60 
billion annually by 2020, however 
most of these pharmaceutical 
products are imported with local 
production accounting for 10 to 30% 
depending on the country. For local 
production, active pharmaceutical 
ingredients (APIs) and excipients are 
imported and the bulk of activities 
are on generic drugs reformulation 
activities. 
Biologicals are a very small component 
of the equation given that activity in 
vaccine and biologicals manufacture 
is limited to a few countries (South 
Africa, Senegal, Tunisia and Egypt) 
in most instances. Clearly the 
current trajectory will not provide 
the health security goals espoused 
in the African Union’s Agenda 2063 
“the Africa We Want”; and new and 
innovative organisational setups are 
required to develop and upgrade the 
pharmaceutical sector to be able to 
meet the needs of the continent now 
and more than fifty years into the 
future. 
The SADC region has demonstrated 
an awareness to this challenge and 
realised that use of appropriate 
pharmaceuticals is central to disease 
treatment and prevention, and 
that access to affordable, safe, and 
quality-assured medicines is uneven 
in Southern Africa. A number of 
challenges work singly or collectively 
to impede access, and these range 
from lack of adequate production 
capabilities, inefficient supply chains, 
an uncoordinated regulatory terrain, 
to lack of standardised legislation for 
pharmaceutical, and unreliable water, 
energy and transport infrastructure to 
health systems’ usage and disparate 
treatments for diseases. 
Among the five case study countries, 
there is a challenge of high cost of 
medicines due to factors related to, 
among others, logistical challenges, 
diminishing capacities of local 
pharmaceutical manufacturers, 
leading to reliance on imported 
medicines, particularly for Botswana, 
Namibia, Zambia and Zimbabwe 
(Mugwagwa, 2019). South Africa has 
accumulated industrial capabilities 
(or potential) for manufacturing 
medicines and a wide range of medical 
technologies. Its pharmaceutical 
industry (large multinational 
corporates and a few local firms) 
is relatively well established when 
compared to the other SADC 
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countries. Zimbabwe’s pharmaceutical 
manufacturing capabilities have 
shrunk considerably in the last two 
decades due to skills and capital flights 
in the backdrop of economic and 
political challenges (Banda, 2016). 
approaches
The original idea of the health-
industry complex by Mackintosh et al 
(2016) conceptualised the relationship 
between pharmaceutical industry 
and the public health sector and the 
potential synergistic relationships 
that can be capitalised for innovation, 
industry development and health 
security simultaneously. 
We are cognisant of the arguments 
surrounding PPPs, and we focus on 
the positive they can deliver in difficult 
circumstances where solely public 
or private investment may not yield 
much when the funding magnitude, 
risks inherent and the gestation 
period as well as policy terrain are 
insurmountable.
Using mixed methods, we assessed 
the dynamics of PPPs as a viable 
financing mechanism for investment in 
the pharmaceutical sector (drugs and 
vaccines) that leads to better social 
inclusion in health (medicines access, 
affordability and security) through the 
health and industrialisation complex. 
FINDINGS AND 
IMPLICATIONS
Despite an increase in research 
investigating the roles of PPPs 
globally and elsewhere in Africa, 
there is limited understanding on the 
distribution and make up of health 
PPPs in Southern African countries. 
To contribute towards filling this 
gap, we obtained empirical evidence 
from five countries Botswana, 
Namibia, South Africa, Zambia and 
Zimbabwe and explored potential 
avenues on how health PPPs can be 
deployed to leverage private sector 
resources and expertise to drive 
government goals of optimising the 
efficiency and cost-effectiveness 
of the PPP model in health service 
delivery. Southern African countries, 
previously viewed as the epicentre 
of HIV/AIDS are an important source 
of insights, experiences and lessons 
for global health researchers and 
policymakers on the role of PPPs in 
building competitive health-industry 
complexes in the study countries and 
other LMICs.
 
The policy environment is ready 
This study established that while the 
core provision of healthcare services is 
primarily viewed as the responsibility 
of governments, policymakers 
increasingly recognise that in evolving 
health contexts, private actors’ capital 
and expertise can be a central driver 
for improving both cost-efficiency and 
overall health system effectiveness, 
through enhanced access to services 
and the introduction of innovative 
technologies and service delivery 
modes. 
In the last two decades, in all the 
study countries, governments have 
taken a centre stage in attaining and 
sustaining the appropriate balance 
between public and private sector 
resources both for financing and 
managing health services. PPPs 
have thus been viewed as a viable 
mechanism for ensuring optimal 
deployment of scarce resources to 
advance public health goals, across 
the dimensions of equity, access, cost-
effectiveness and quality of healthcare 
provision. 
PPPs in healthcare have been 
mechanisms for governments to 
leverage private sector resources 
and expertise to deliver public 
health objectives whilst balancing 
and maximising private sector’s 
strengths in rapid decision making, 
better skills base, flexible human 
resource practices and quick resource 
acquisition and appropriation.
Shared language and understanding
This study also established that across 
the target countries, there is no 
common definition for PPPs nor is the 
terminology necessarily universally 
applicable, as other authors have also 
noted. The authors though agree that 
dominant notion underpinning PPPs is 
about ‘… working arrangements based 
on a mutual commitment (over and 
above that implied in any contract) 
between a public-sector organisation 
with any organisation outside of the 
public sector (Bovard, 2004)’. 
This broad conceptualisation allowed 
us to capture different configurations 
associated with the PPP model 
recognising that PPP actors cut across 
a range of sectors and roles including, 
pharmaceutical manufacturing, policy 
design, implementation, activism, 
procurement and supply chain and 
policy monitoring and evaluation (see 
Table 1).
Key drivers and success factors
Policymakers and governments, 
burdened by economic constraints 
and difficult geographies, still have 
to contend with the complexity and 
uncertainty of global health challenges 
whilst trying to solve intractable local 
health challenges in many instances 
burdened by neglected diseases.
Consequently key drivers for PPPs 
established by this study to address 
the aforementioned include but are 
not limited to the following: 
• PPPs are better placed to address 
market deficiencies, through 
risk sharing, across multiple 
stakeholders and projects. This is 
relevant in contexts of emerging 
technologies and innovations 
where associated ‘high technical 
risks’ may be viewed by traditional 
funders as outweighing the 
short term visible economic 
benefits, and governments 
may be balancing a number of 
development and social initiatives.
• PPPs aid economies of scale, 
particularly of procurement, 
service provision but also 
research and development and 
manufacturing.
• PPPs can be ‘system integrators’ 
where knowledge and ideas are 
leveraged across sectors, for 
instance across industry, academia 
and government as seen in PPPs 
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Table 1: Southern African examples of PPPs in the health-industry complex
COUNTRY SELECTED HEALTH PPP EXAMPLES
Zimbabwe • Government and local pharma partnership in manufacturing of ARVs (Gov. of 
Zimbabwe-NATPHARM-Local manufacturers)
• International agency, government and local pharma partnership for procure-
ment of essential medicines (European Union-Gov. of Zimbabwe-NATPHA-
RM-local manufacturers)
• Government, non-profit and private sector partnerships in health service deliv-
ery (Gov. of Zimbabwe-private hospitals and mission hospitals)
• Public-private co-location health delivery models (e.g. private wards in public 
hospitals such as Parirenyatwa Hospital)
South Africa • Public-private co-location in clinical care management Universitas and Pel-
anomi Hospital in Free State Province; Humansdorp District Hospitals in the 
Eastern Cape Province
• Public-private asset financing and maintenance and management partnership, 
e.g. The Inkosi Albert Luthuli Central Hospital in KwaZulu Natal Province
• Public-private equity partnership for vaccine and sera manufacture, e.g. Biovac 
Institute and Govt. of South Africa
Botswana • Public-private research and innovation generation partnership, e.g. Botswana 
Harvard HIV/AIDS vaccine partnership between Botswana Government and 
Harvard University
• Public-private infrastructure design and development partnership, e.g. BOTUSA 
project (Botswana Ministry of Health, the US centre for disease control and 
the Global AIDS programme) on Prevention of Mother to child transmission 
(PMTCT) now integrated into national HIV programme.
• Public-private partnership for research into and manufacture of vaccines for 
livestock, e.g. Botswana Vaccine Institute, a partnership between a private 
Livestock Pharma Company (Merial – Sanofi) and Govt. of Botswana
Namibia • Public-private partnership in research and innovation generation, e.g. Equip 
Health and Ministry of Health for an experimental clinical trial on pre-exposure 
prophylaxis (PrEP) using Gilead’s Truvada
• Public-private partnership in infrastructure design and development between 
ACHAP and Ministry of Health for infrastructural development of clinics and 
HIV health-facilities
• Public-private partnership in health service delivery, e.g. diagnostics access and 
screening services partnership between Pharmaccess, MOHSS, NABCOA and 
Namibia Institute of Pathology
Zambia • Public-private partnership in research and innovation generation, e.g. Global 
Alliance for Vaccines initiative (GAVI) partnership with Ministry of Health to 
drive the roll out of the pneumococcal vaccine
• Public-private partnerships in infrastructure design and development, e.g. 
construction of supply chain and distribution regional hubs in Chipata, Mpika, 
Mansa, and Choma, a partnership between Medical Stores Limited (supported 
by Global Fund, USAID and European Union).
• Public-non-profit partnerships in training, diagnostics, preventative, curative 
and palliative services, e.g. partnership between Churches Health Association 
of Zambia (CHAZ) and the Govt. of Zambia
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in health financing, access to 
antiretroviral (ARV) drugs for HIV, 
and market access for diagnostics 
and treatments for care for HIV, 
TB and Malaria. 
 
As illustrated in Table 1, this study 
established the presence of various 
PPP configurations. These include 
partnerships where partners are 
drawn from non-governmental 
organisations (NGOs), donor agencies, 
industry, and other for-profit and 
non-profit enterprises, academia 
and social enterprises which link 
with governments to address specific 
maladies, intra-system issues, as a 
route to achieving better and a more 
responsive and resilient health system. 
This study contributes literature 
on the roles of PPPs in addressing 
global health inequity through 
market adjustment, connection 
of pharmaceutical suppliers with 
poor populations in low-middle 
income countries to drive overall 
health (social) inclusion, unpacking 
an array of context-specific social, 
economic, political, geographic, 
and epidemiological factors which 
cannot be successfully examined if 
the lens is not anchored on the sub-
regional, regional and global political 
economies. 
The study has thus expanded literature 
for the southern African region which 
hitherto disproportionately focused on 
public-private engagement in South 
Africa, with very little known about the 
other countries, outside of Zimbabwe 
and Mozambique, in which narratives 
on the health-industry complex from 
the perspectives of pharmaceutical 
manufacturing have only been 
recently captured (Mackintosh et al., 
2016).
CONCLUSIONS
1. PPPs are prevalent and present 
innovative financing mechanisms 
which drive social inclusion. 
The case studies presented 
showcased how the potential 
avenues for advancing 
government’s efficiency in 
health spending, deploying and 
leveraging the private sector 
(profit and non-profit) resources 
and human resources and skills, 
the effectiveness of private and 
public-sector engagements, can 
be maximised.
 
2. The peculiar contextual realities 
of PPPs remain markedly under-
researched.
PPPs in health are distinct from 
typical infrastructure projects 
PPPs. Apart from the transient 
and predominantly philanthropy 
driven nature of PPPs in some of 
the study countries, this study 
also established cases where 
health PPPs do not fit into the 
conventional models of PPPs 
(e.g. BOT or BOOT), yet still being 
within the conventional reasons 
why PPPs are initiated, e.g. to fill 
gaps in supply. 
We demonstrated in the 
case studies that some PPPs 
motivations go beyond this 
in their design and/or in their 
operations. What stands out 
for health PPPs is that primarily, 
private financial contribution 
is usually low, and as a result, 
these projects require a large 
and ongoing payment from 
government procurement. In 
addition, the ongoing expenses 
of operating a hospital or 
other medical facility represent 
the vast majority of project 
costs, as opposed to a typical 
infrastructure project in which 
capital expenditures (capex) are 
the main cost element.
3. Factors limiting the effectiveness 
of governance, incentive and 
policy frameworks 
This paper established the 
existence of different mechanisms 
for governing and incentivising 
PPPs. We also established that 
governments assume multiple 
roles as regulators, facilitators, 
funders of innovation and as 
well as investors in PPPs. These 
multiple roles could be leveraged 
for identification and deployment 
of needed political champions for 
PPPs in the study countries. 
Further, we noted the catalytic 
role that PPPs play, and how they 
serve as sources of collateral 
capacities for new partnerships 
and for other sectors of the 
economy. Successful PPPs such as 
Biovac in South Africa have shown 
ability to collaborate with both 
private and philanthropic actors in 
pursuing technology transfer and 
technological learning. 
The government as in the case of 
Biovac can, through departments 
such as Department for Science 
and Technology, act as both 
brokers and integrators actively 
supporting the creation of an 
innovation ecosystem in the local 
production of pharmaceuticals. 
Such pervasive impact and 
potential should be harnessed for 
structuring incentive structures 
and governance mechanisms 
which are responsive and able 
to enhance the relevance and 
contributions of PPPs to health 
system strengthening.
RECOMMENDATIONS 
1. We recommend continuous 
appraisal and documentation 
of the role and contributions 
of different actors to PPPs, for 
example, how government can 
support local pharmaceutical 
production through:
• Innovative procurement by 
assuring markets for products; 
• Public funding of research in 
universities and institutes de-risks 
the early stages of innovation and 
technology development. 
• Invest in capabilities and 
resources for coordination in 
order for the broad range of 
benefits from partnerships to be 
realised. 
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Whilst the argument 
underpinning the need for 
metrics is self-evident, it is 
perhaps more prudent to ask how 
the technological, intellectual, 
industrial, and research-driven 
insights drawn from the PPP 
model can be effectively 
mobilised to tackle current and 
future health demands. In so 
doing, important contributions 
will be made towards nuanced 
context-specific narratives, rather 
than predominantly quantitative 
ideological argumentations 
critiquing the PPP model in health 
delivery. 
2. We recommend a Partnership 
Impact Index which SGCI and 
SADC could develop to offer 
annual awards for impactful 
partnerships in some of the 
pressing and persistent health 
challenge areas, e.g. HIV/AIDS. 
This could also potentially include 
a proactive dimension identifying, 
nurturing and rewarding 
innovative partnerships that are 
helping countries to cope with 
NCDs. 
A related idea would be the 
development of partnership/
partner relevance indexes which 
would be deployed to assess 
the relevance and salience of 
partnerships/partners. 
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